SEC filings and other documents

Anaphylm is set for launch, targeting unmet needs with strong clinical and commercial readiness.

Anaphylm's rapid, user-friendly delivery and strong clinical profile position it for major market impact.

Q2 2026 revenue rose 38% year-over-year; Anaphylm NDA resubmission and launch prep on track.

FDA progress, global expansion, and all proposals passed with strong shareholder support.

Q1 2026 delivered 66% revenue growth, narrowed losses, and key Anaphylm regulatory advances.

Anaphylm's NDA resubmission is on track for Q3, with launch prep backed by strong cash reserves.

Anaphylm targets Q3 2024 resubmission, with strong financials and market readiness.

Anaphylm sublingual film targets FDA approval in Q1 2027, aiming to disrupt the allergy market.

FDA requires new human factors and PK studies for Anaphylm; resubmission expected by Q3.

Anaphylm NDA resubmission on track, 2025 net loss $83.8M, 2026 revenue guidance up to $50M.

Anaphylm is set for a focused Q1 launch, backed by strong data, funding, and regulatory progress.

Strong Q3 results and financing position company for Anaphylm launch, pending FDA approval.

Innovative oral film pipeline targets $2B epinephrine market with rapid, device-free solutions.

Anaphylm sublingual film targets rapid, needle-free anaphylaxis relief with U.S. launch in 2025.

FDA signals positive review for Anaphylm; launch and global expansion plans are well-funded.

Anaphylm nears FDA review as Q2 revenue rises to $10M, with launch and financing preparations on track.